Research in Pediatrics & Neonatology · 2020 · 32 citations · 9 references
Veterinary MedicineInfectious DiseasesPharmacotherapyInfectious Disease PharmacotherapyMolecular VirologyVirologyAntiviral PharmacologyAntiviral TherapyTreatmentViral InfectionsAngiotensin Ii Receptor BlockersAntiviral TherapeuticsSars-cov-2 Antiviral TherapySars-cov-2 InfectionTherapeutic Targeting Of Viral EntryViral Entry ReceptorsViral Infection TreatmentViral Spreading
Since the outbreak in China in December 2019 researchers searching for adequate therapy to control viral spreading and to inhibit COVID-19 effectively. To date, no effective drug to treat this severe viral infection was found. Publications about angiotensin II receptor blocker reveal a new effective method to think about in treating COVID-19 [1-5]. Moreover, different therapy options were started to stop the devastating potential of COVID-19 worldwide. Antibody-rich donated plasma from survivors, different inhibitors are part of analysis to stop the entry of the virus into the cell and disturb the connection between SARS-CoV-2 and angiotensin-2 receptor binding. Angiotensin II and the receptor play an important role in cell entry of COVID-19. For cell entry COVID-19 needs the presence of a serine protease TMPRSS2 and cathepsin L [6-9].
9
Claudine Kumba · Acta Scientific Paediatrics · 2019 · 27 citations · Full text
Medicine, Pediatrics, Surgery +17